Research Progress of Hypertension in Postmenopausal Women

doi:10.3969/j.issn.1007-9572.2016.26.024

Abstract

Abstract: As a globally concerned public health problem，hypertension severely affects patients’ quality of life.The hypertension of women after one-year physiological menopause is called postmenopausal hypertension.With the decreasing of estrogen levels，postmenopausal hypertension is in an increasing tendency，and hypertension is a main risk factor of women cardiovascular disease.Therefore，the key factor of preventing cardiovascular events is to improve the awareness and management of postmenopausal hypertension.The paper reviews the research progress in the cause of disease，pathogenesis and therapeutic method so as to improve postmenopausal women’s awareness of postmenopausal hypertension.

Key words: Hypertension, Postmenopause, Femininity

摘要： 　　高血压作为全球关注的公共健康问题，严重影响患者的生活质量。女性生理性绝经1年后出现的血压升高称为绝经后高血压，随着绝经后雌激素水平的降低，绝经后高血压呈明显增加趋势，而高血压是女性心血管疾病的主要危险因素。因此提高绝经后高血压的认识和管理是预防心血管疾病发生的关键因素。本文对绝经后高血压发生的相关因素、发病机制、治疗方法的研究进展进行综述，以期提高绝经后女性对绝经后高血压的认识。

关键词: 高血压, 绝经后期, 女性

ZHAO Xu, YU Jing. Research Progress of Hypertension in Postmenopausal Women[J]. Chinese General Practice, 2016, 19(26): 3243-3247.

赵旭, 余静. 绝经后高血压的研究进展[J]. 中国全科医学, 2016, 19(26): 3243-3247.

References

［1］陈伟伟，高润霖，刘力生，等.中国心血管病报告2013概要［J］.中国循环杂志，2014，29（7）：487-491. ［2］LEE J S，HAYASHI K，MISHRA G，et al.Independent association between age at natural menopause and hypercholesterolemia，hypertension，and diabetes mellitus：Japan nurses’ health study［J］.J Atheroscler Thromb，2013，20（2）：161-169. ［3］HE J，GU D，WU X，et al.Major causes of death among men and women in China［J］.N Engl J Med，2005，353（11）：1124-1134. ［4］KAMEL H，NAVI B B，SRIRAM N，et al.Risk of a thrombotic event after the 6-week postpartum period［J］.N Engl J Med，2014，370（14）：1307-1315. ［5］丁立群，姜玲，范洁.吸烟加重高血压病患者大中动脉硬化［J］.中华高血压杂志，2008，16（1）：26-28. ［6］HERNANDEZ SCHULMAN I，RAIJ L.Salt sensitivity and hypertension after menopause：role of nitric oxide and angiotensin Ⅱ［J］.Am J Nephrol，2006，26（2）：170-180. ［7］FORD E S，LI C，ZHAO G，et al.Trends in obesity and abdominal obesity among adults in the united states from 1999—2008［J］.Int J Obes（Lond），2011，35（5）：736-743. ［8］FLEGAL K M，CARROLL M D，OGDEN C L，et al.Prevalence and trends in obesity among US adults，1999—2008［J］.JAMA，2010，303（3）：235-241. ［9］LOBO R A.Metabolic syndrome after menopause and the role of hormones［J］.Maturitas，2008，60（1）：10-18. ［10］OZBEY N，SENCER E，MOLVALILAR S，et al.Body fat distribution and cardiovascular disease risk factors in pre- and postmenopausal obese women with similar BMI［J］.Endocr J，2002，49（4）：503-509. ［11］ROSSI R，NUZZO A，ORIGLIANI G，et al.Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women［J］.Hypertension，2008，52（5）：865-872. ［12］KHOKHAR K K，SIDHU S，KAUR G.Correlation between leptin level and hypertension in normal and obese pre- and postmenopausal women［J］.Eur J Endocrinol，2010，163（6）：873-878. ［13］BELIN DE CHANTEMLE E J，MINTZ J D，RAINEY W E，et al.Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice［J］.Hypertension，2011，58（2）：271-279. ［14］LUKANOVA A，LUNDIN E，ZELENIUCH-JACQUOTTE A，et al.Body mass index，circulating levels of sex-steroid hormones，IGF-I and IGF-binding protein-3：a cross-sectional study in healthy women［J］.Eur J Endocrinol，2004，150（2）：161-171. ［15］STEINER M，DUNN E，BORN L.Hormones and mood：from menarche to menopause and beyond［J］.J Affect Disord，2003，74（1）：67-83. ［16］GOLDSTEIN B I，FAGIOLINI A，HOUCK P，et al.Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States［J］.Bipolar Disord，2009，11（6）：657-662. ［17］BRASZKO J J，KARWOWSKA-POLECKA W，HALICKA D，et al.Captopril and enalapril improve cognition and depressed mood in hypertensive patients［J］.J Basic Clin Physiol Pharmacol，2003，14（4）：323-343. ［18］FERNNDEZ-VEGA F，ABELLN J，VEGAZO O，et al.Angiotensin Ⅱ type 1 receptor blockade to control blood pressure in postmenopausal women：influence of hormone replacement therapy［J］.Kidney Int Suppl，2002（82）：S36-41. ［19］SCHUNKERT H，DANSER A H，HENSE H W，et al.Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women［J］.Circulation，1997，95（1）：39-45. ［20］MANSEGO M L，REDON J，MARIN R，et al.Renin polymorphisms and haplotypes are associated with blood pressure levels and hypertension risk in postmenopausal women［J］.J Hypertens，2008，26（2）：230-237. ［21］RAMOS-FILHO A C，A FARIA J，CALMASINI F B，et al.The renin-angiotensin system plays a major role in voiding dysfunction of ovariectomized rats［J］.Life Sci，2013，93（22）：820-829. ［22］YANES L L，ROMERO D G，ILIESCU R，et al.Postmenopausal hypertension：role of the renin-angiotensin system［J］.Hypertension，2010，56（3）：359-363. ［23］OLSZANECKA A，POSNIK-URBASKA A，KAWECKA-JASZCZ K，et al.Adipocytokines and blood pressure，lipids and glucose metabolism in hypertensive perimenopausal women［J］.Kardiol Pol，2010，68（7）：753-760. ［24］PELZER T，DE JAGER T，MUCK J，et al.Oestrogen action on the myocardium in vivo：specific and permissive for angiotensin-converting enzyme inhibition［J］.J Hypertens，2002，20（5）：1001-1006. ［25］LANGRISH J P，MILLS N L，BATH L E，et al.Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure［J］.Hypertension，2009，53（5）：805-811. ［26］AFFINITO P，PALOMBA S，BONIFACIO M，et al.Effects of hormonal replacement therapy in postmenopausal hypertensive patients［J］.Maturitas，2001，40（1）：75-83. ［27］ROSSOUW J E，ANDERSON G L，PRENTICE R L，et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women：principal results from the women’s health initiative randomized controlled trial［J］.JAMA，2002，288（3）：321-333. ［28］HERRINGTON D M.The HERS trial results：paradigms lost？Heart and Estrogen/progestin Replacement Study［J］.Ann Intern Med，1999，131（6）：463-466. ［29］GRADY D，HERRINGTON D，BITTNER V，et al.Cardiovascular disease outcomes during 6.8 years of hormone therapy：Heart and Estrogen/progestin Replacement Study follow-up（HERS Ⅱ）［J］.JAMA，2002，288（1）：49-57. ［30］PRELEVIC G M，KWONG P，BYRNE D J，et al.A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women［J］.Fertil Steril，2002，77（5）：945-951. ［31］HARMAN S M，VITTINGHOFF E，BRINTON E A，et al.Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes［J］.Am J Med，2011，124（3）：199-205. ［32］KALANTARIDOU S N，NAKA K K，PAPANIKOLAOU E，et al.Impaired endothelial function in young women with premature ovarian failure：normalization with hormone therapy［J］.J Clin Endocrinol Metab，2004，89（8）：3907-3913. ［33］KLING J M，LAHR B A，BAILEY K R，et al.Endothelial function in women of the Kronos Early Estrogen Prevention Study［J］.Climacteric，2015，18（2）：187-197. ［34］WEINER C P，LIZASOAIN I，BAYLIS S A，et al.Induction of calcium-dependent nitric oxide synthases by sex hormones［J］.Proc Natl Acad Sci U S A，1994，91（11）：5212-5216. ［35］ROMERO J C，RECKELHOFF J F.State-of-the-Art lecture.Role of angiotensin and oxidative stress in essential hypertension［J］.Hypertension，1999，34（4 Pt 2）：943-949. ［36］RECKELHOFF J F，ROMERO J C.Role of oxidative stress in angiotensin-induced hypertension［J］.Am J Physiol Regul Integr Comp Physiol，2003，284（4）：R893-912. ［37］IARREA P，CASANOVA A，ALAVA M A，et al.Melatonin and steroid hormones activate intermembrane Cu，Zn-superoxide dismutase by means of mitochondrial cytochrome P450［J］.Free Radic Biol Med，2011，50（11）：1575-1581. ［38］NICKENIG G，BUMER A T，GROH C，et al.Estrogen modulates AT1 receptor gene expression in vitro and in vivo［J］.Circulation，1998，97（22）：2197-2201. ［39］GALLAGHER P E，LI P，LENHART J R，et al.Estrogen regulation of angiotensin-converting enzyme mRNA［J］.Hypertension，1999，33（1 Pt 2）：323-328. ［40］DIAMANTI-KANDARAKIS E.Polycystic ovarian syndrome：pathophysiology，molecular aspects and clinical implications［J］.Expert Rev Mol Med，2008（10）：e3. ［41］CHEN M J，YANG W S，YANG J H，et al.Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome［J］.Hypertension，2007，49（6）：1442-1447. ［42］SHAW L J，BAIREY MERZ C N，AZZIZ R，et al.Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival：results from the National Institutes of Health-National Heart，Lung，and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation［J］.J Clin Endocrinol Metab，2008，93（4）：1276-1284. ［43］BALTATU O，CAYLA C，ILIESCU R，et al.Abolition of hypertension-induced end-organ damage by androgen receptor blockade in transgenic rats harboring the mouse ren-2 gene［J］.J Am Soc Nephrol，2002，13（11）：2681-2687. ［44］LAUGHLIN G A，BARRETT-CONNOR E，KRITZ-SILVERSTEIN D，et al.Hysterectomy，oophorectomy，and endogenous sex hormone levels in older women：the Rancho Bernardo Study［J］.J Clin Endocrinol Metab，2000，85（2）：645-651. ［45］KASSAB S，KATO T，WILKINS F C，et al.Renal denervation attenuates the sodium retention and hypertension associated with obesity［J］.Hypertension，1995，25（4 Pt 2）：893-897. ［46］HAYNES W G，MORGAN D A，DJALALI A，et al.Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic［J］.Hypertension，1999，33（1 Pt 2）：542-547. ［47］HOGARTH A J，BURNS J，MACKINTOSH A F，et al.Sympathetic nerve hyperactivity of essential hypertension is lower in postmenopausal women than men［J］.J Hum Hypertens，2008，22（8）：544-549. ［48］KRUM H，SCHLAICH M P，SOBOTKA P A，et al.Percutaneous renal denervation in patients with treatment-resistant hypertension：final 3-year report of the Symplicity HTN-1 study［J］.Lancet，2014，383（9917）：622-629. ［49］ESLER M D，KRUM H，SCHLAICH M，et al.Renal sympathetic denervation for treatment of drug-resistant hypertension：one-year results from the symplicity HTN-2 randomized，controlled trial［J］.Circulation，2012，126（25）：2976-2982. ［50］KANDZARI D E，BHATT D L，SOBOTKA P A，et al.Catheter-based renal denervation for resistant hypertension：rationale and design of the SYMPLICITY HTN-3 Trial［J］.Clin Cardiol，2012，35（9）：528-535. ［51］WILKINS F C Jr，ALBEROLA A，MIZELLE H L，et al.Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin［J］.Am J Physiol，1995，268（2 Pt 2）：R375-381. ［52］MORTENSEN L H，PAWLOSKI C M，KANAGY N L，et al.Chronic hypertension produced by infusion of endothelin in rats［J］.Hypertension，1990，15（6 Pt 2）：729-733. ［53］CHEN L，ACKERMAN R，SALEH M，et al.20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo［J］.J Pharmacol Exp Ther，2014，348（3）：442-451. ［54］WARD N C，RIVERA J，HODGSON J，et al.Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans［J］.Circulation，2004，110（4）：438-443. ［55］LIMA R，YANES L L，DAVIS D D，et al.Roles played by 20-HETE，angiotensin Ⅱ and endothelin in mediating the hypertension in aging female spontaneously hypertensive rats［J］.Am J Physiol Regul Integr Comp Physiol，2013，304（3）：R248-251. ［56］MOSCA L，BANKA C L，BENJAMIN E J，et al.Evidence-based guidelines for cardiovascular disease prevention in women：2007 update［J］.Circulation，2007，115（11）：1481-1501. ［57］MARUTHUR N M，WANG N Y，APPEL L J.Lifestyle interventions reduce coronary heart disease risk：results from the PREMIER Trial［J］.Circulation，2009，119（15）：2026-2031. ［58］HAYOZ D，ZAPPE D H，MEYER M A，et al.Changes in aortic pulse wave velocity in hypertensive postmenopausal women：comparison between a calcium channel blocker vs angiotensin receptor blocker regimen［J］.J Clin Hypertens（Greenwich），2012，14（11）：773-778. ［59］POSADZY-MALACZYNSKA A.Menopause as a cardiovascular risk factor：therapeutic implications of hypertension［J］.Menopausal Review，2011，15（1）：40-44. ［60］隆海文，黄燕春，黄忠力.依那普利联合辛伐他汀对绝经后高血压患者颈动脉硬化的影响［J］.实用医学杂志，2011，27（16）：3043-3045. ［61］MODENA M G，ROSSI R，MUIA N Jr，et al.Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension［J］.G Ital Cardiol，1998，28（6）：636-644. ［62］PERRONE G，CAPRI O，GALOPPI P，et al.Menopausal symptoms after the discontinuation of long-term hormone replacement therapy in women under 60：a 3-year follow-up［J］.Gynecol Obstet Invest，2013，76（1）：38-43. ［63］郭玉田.卡托普利联合黛力新治疗女性更年期高血压50例分析［J］.中国实用神经疾病杂志，2012，15（8）：61-62. ［64］周伯荣，卢雄，钟向红，等.抗焦虑抑郁药物对更年期女性高血压患者的协助治疗［J］.中华高血压杂志，2007，15（1）：53-56. ZHOU B R，LU X，ZHONG X H，et al.The adjunctive effect of the anti-anxiety-depression drugs on the treatment of essential hypertension in menopause women［J］.Chinese Journal of Hypertension，2007，15（1）：53-56. ［65］余承云，林雪.中医药治疗更年期高血压研究概述［J］.现代中西医结合杂志，2009，18（2）：218-220. ［66］李莹莹，胡骏，秦志慧，等.加味逍遥丸联合缬沙坦治疗围绝经期高血压病临床研究［J］.新中医，2012，44（12）：63-65. LI Y Y，HU J，QIN Z H，et al.Clinical observation of modified Xiaoyao powder combined with valsartan for treatment of climacteric hypertension［J］.Journal of New Chinese Medicine，2012，44（12）：63-65. ［67］蔡勇.补肾活血方配合氯沙坦治疗女性更年期高血压病60例临床观察［J］.中医药导报，2011，17（4）：39-40. ［68］赵圣艳，林雪.中西医结合治疗女性更年期高血压疗效的Meta分析［J］.中国实验方剂学杂志，2015，21（11）：198-202.

[1]	LI Jie, YANG Xinhui, CAO Li, ZHANG Jing, JIANG Yue. Case Analysis of General Practice Diagnosis and Treatment in a "Three High" Patient with Coexistence and Fatty Liver Disease [J]. Chinese General Practice, 2026, 29(06): 810-816.
[2]	ZHOU Wenchao, LIANG Jiaqi, YAO Shangman, XUE Zhao, LIU Long, GUO Xiangjie. Identification of Shared Loci between Hypertension and Parkinson's Disease [J]. Chinese General Practice, 2026, 29(02): 201-206.
[3]	NIE Qianqian, CHENG Guirong, SONG Dan, LI Jingyao, XU Lang, ZHANG Lijuan. Study on the Relationship between Hypertension and Its Comorbidity and Dementia in Chinese Community-dwelling Older Adults [J]. Chinese General Practice, 2026, 29(01): 76-83.
[4]	CHEN Yufei, ZHAO Qian, XIEYIRE· Hamulati, CAI Liting, LI Xiaomei, YANG Yining, LIU Fen. Association between Life's Essential 8 Score and Hypertension Risk: a Cross-Sectional Study in the Rural and Pastoral Population of Altay Prefecture, Xinjiang [J]. Chinese General Practice, 2026, 29(01): 91-99.
[5]	ZHAO Lingyu, HAO Xiaoning, FENG Zhiqiang. Fuzzy Comprehensive Evaluation of Implementation Effect of Medical and Prevention Integration Based on Residents' Perception [J]. Chinese General Practice, 2026, 29(01): 115-121.
[6]	ZHANG Ying, LIAO Xiaoyang, YANG Hanfei, YU Yongjun, LIU Lidi, JIA Yu, SHEN Can, LI Xiao, HUANG Chuanying, YANG Rong. Interpretation of the 2024 International Society of Hypertension Position Paper on Innovations in Blood Pressure Measurement and Reporting Technology and Its Implications for China [J]. Chinese General Practice, 2025, 28(36): 4541-4549.
[7]	YU Xinyan, YANG Jianyun, JIANG Qingru, CHEN Tao, SU Peng, WANG Siyang, LUO Zhanwu, ZHANG Haicheng. Study on the Correlation between the Course of Hypertension and Autonomic Nervous System Damage in Elderly Patients in Primary Care Institutions in Ningxia Hui Autonomous Region Based on Single Lead Wearable Electrocardiogram Device [J]. Chinese General Practice, 2025, 28(34): 4359-4370.
[8]	MA Nian, WANG Ziyun, TENG Xiaoyan, CHEN Yun, SUN Zhengyong. Study on the Current Situation and Influencing Factors of Comorbidities among Urban-rural Elderly Hypertensive Patients [J]. Chinese General Practice, 2025, 28(34): 4344-4350.
[9]	YANG Yingtian, LYU Qianyu, WU Qian, HOU Xinzheng, SONG Jianjun, YE Xuejiao, YANG Chenyan, WANG Shihan. Efficacy of Five-body Balance Exercise on Obesity-related Hypertension Based on the Rehabilitation Model of "Hospital-Gym-Community" : a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(32): 4038-4046.
[10]	LIU Chunyan, DENG Zhaohui, SONG Yingbo, YANG Fang, SHI Qian, LI Yongxin, ZHANG Xin. Comparison of Prevalence and Comorbidity of Hypertension, Diabetes and Dyslipidemia in Xinjiang Residents [J]. Chinese General Practice, 2025, 28(32): 4031-4037.
[11]	DAI Tiangu, HE Qing, GAO Xuefei, ZHANG Gaoyu, FAN Jiarong, WANG Zihan, XIAO Xiang, LI Lin. The Predictive Value of Combined Detection of Brachial-ankle Pulse Wave Velocity, Serum Total Cholesterol and N-terminal Pro-B-type Natriuretic Peptide for Coronary Heart Disease in Patients with Essential Hypertension [J]. Chinese General Practice, 2025, 28(32): 4061-4066.
[12]	ZHAO Jie, WANG Yijing, LIU Gang, HAN Xinxin. Effect of Digitally Enabled Generalist-Specialist Collaborative Care on Hypertension Management Capacity at Community Health Centers in China: a Difference-in-Differences Analysis [J]. Chinese General Practice, 2025, 28(31): 3904-3911.
[13]	TU Kunkun, ZHAO Jie, SHI Xiuyuan, XIE Pei, HAN Xinxin. The Impact of Generalist-Specialist Collaborative Care Models on Health Outcomes in Hypertension and Diabetes: a Systematic Review and Meta-analysis in China [J]. Chinese General Practice, 2025, 28(31): 3912-3923.
[14]	WU Wenjun, WEI Jingjing, LI Xue, REN Hongjie, YU Rui, PENG Guangcao, ZHU Mingjun. Regularity of Prescriptions for Coronary Heart Disease with Hypertension Based on Latent Structure and Association Rules [J]. Chinese General Practice, 2025, 28(30): 3787-3795.
[15]	BAI Jiaxin, CHEN Yu, ZHOU Yiheng, LIU Lidi, YANG Rong, YAO Yi, YUAN Bo, ZHANG Yonggang, LEI Yi, ZENG Rui, JIA Yu, LIAO Xiaoyang. Assessment and Treatment of Early-onset Hypertension: Position Statement of the British and Irish Hypertension Association and Its Implications for Clinical Management of Early-onset Hypertension in China [J]. Chinese General Practice, 2025, 28(30): 3741-3746.